Why the study?
HFpEF involves multiple pathophysiological mechanisms causing heterogeneous phenotypes that have confounded previous trials, requiring better biological understanding to guide targeted therapies.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Should not yet alter HFpEF management; leaves open which biological phenotypes are causal targets for therapy.
Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypes of HFpEF and therapeutic interventions aimed at targeting these phenotypes.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: